Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964498 | 0.96 | TLR7 (0.64) | TLR7IL6 | |
| SCHEMBL1501678 | 0.94 | TLR7 (0.65) | TLR7IL6 | |
| SCHEMBL4666608 | 0.94 | TLR7 (0.61) | TLR7IL6 | |
| SCHEMBL29071883 | 0.91 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL2837664 | 0.89 | TLR7 (0.68) | TLR7IL6 | |
| SCHEMBL4634229 | 0.89 | TLR7 (0.53) | TLR7 | |
| SCHEMBL4633208 | 0.89 | TLR7 (0.53) | TLR7 | |
| Hydrochloric Acid SCHEMBL3360874 | 0.89 | TLR7 (0.67) | TLR7IL6 | |
| Bromide SCHEMBL3363812 | 0.89 | TLR7 (0.67) | TLR7IL6 | |
| SCHEMBL2589596 | 0.88 | TLR7 (0.77) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | claimed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | claimed |
| EP-3094624-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2016-11-23 | — | — | EP | claimed |
| EP-3068774-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2015109130-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2015-07-23 | — | — | WO | claimed |
| WO-2015073774-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | claimed |
| EP-2794565-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2014-10-29 | — | — | EP | claimed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4103567-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2022-12-21 | — | — | EP | disclosed |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-09-09 | — | — | US | disclosed |
| WO-2021160617-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2021-08-19 | — | — | WO | disclosed |
| EP-3833672-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-06-16 | — | — | EP | disclosed |
| WO-2019118839-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-3094624-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-3068774-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Novira Therapeutics Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015109130-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015073774-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544141-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | TLR7 639/4885IL6 962/4885 |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, NR1H4 | TLR7 1963/4885IL6 1143/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | TLR7 976/4885IL6 587/4885 |
| US-20210276967-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, HDGF | TLR7 1070/4885IL6 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.